| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | BOCT, BOIT, 24p3R, NGALR, hBOIT, NGALR2, NGALR3 |
| WB Predicted band size | 56 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC22A17 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与SLC22A17抗体相关的文献摘要信息：
1. **"SLC22A17 mediates the uptake of iron-bound lipocalin-2 in human leukemia cells"**
- **作者**: Schmitt R. et al.
- **摘要**: 研究揭示了SLC22A17作为脂质运载蛋白-2(LCN2)的受体，在急性髓系白血病细胞中介导铁转运的功能。该文献利用特异性抗体进行Western blot和免疫荧光实验，证实了SLC22A17在细胞膜上的定位及其与LCN2的结合。
2. **"SLC22A17 expression is epigenetically regulated in acute myeloid leukemia"**
- **作者**: Asano M. et al.
- **摘要**: 分析了SLC22A17在急性髓系白血病(AML)中的表观遗传调控机制，发现其表达受DNA甲基化影响。通过抗体的免疫组化实验，发现SLC22A17低表达与AML患者不良预后相关。
3. **"SLC22A17 modulates cellular iron metabolism through interaction with transferrin receptor 1"**
- **作者**: Yoshikawa M. et al.
- **摘要**: 研究提出SLC22A17通过与转铁蛋白受体1(TfR1)相互作用调节细胞铁代谢。利用抗体的共免疫沉淀技术验证了两者的结合，并发现SLC22A17敲除导致细胞内铁稳态失衡。
4. **"Lipocalin-2 receptor (SLC22A17) is required for renal differentiation and regulates iron trafficking"**
- **作者**: Schmidt-Ott K.M. et al.
- **摘要**: 报道了SLC22A17在肾脏发育和铁运输中的作用，通过抗体阻断实验证明其在肾小管细胞中对脂质运载蛋白-2介导的铁摄取至关重要。
这些文献均涉及SLC22A17抗体的实验应用(如蛋白定位、表达分析或功能研究)，并聚焦于其在铁代谢、癌症或肾脏疾病中的生物学意义。
The SLC22A17 antibody is a research tool targeting the solute carrier family 22 member 17 (SLC22A17), a transmembrane protein initially identified as a receptor for lipocalin-2 (LCN2). SLC22A17. also known as NGAL receptor or 24p3R, belongs to the SLC22 transporter family but functions primarily in ligand binding and signaling rather than solute transport. Structurally, it contains 12 transmembrane domains and localizes to plasma or endosomal/lysosomal membranes. It plays roles in iron homeostasis by mediating cellular uptake of iron-bound lipocalin-2. apoptosis regulation, and innate immunity. SLC22A17 is expressed in kidney, liver, immune cells, and certain cancers. Its dysregulation is linked to tumor progression, chemoresistance, and kidney diseases.
Antibodies against SLC22A17 are used to study its expression patterns, subcellular localization, and interactions in various pathologies. They enable detection via Western blotting, immunohistochemistry, and immunofluorescence. Specificity validation (e.g., knockout controls) is critical due to potential cross-reactivity with other SLC22 family members. Current research focuses on its dual roles in cancer (pro-survival vs. apoptotic signals) and its interplay with iron metabolism. Challenges include distinguishing between isoforms and clarifying context-dependent signaling mechanisms. These antibodies support investigations into therapeutic targeting of SLC22A17-related pathways in inflammation, fibrosis, and oncology.
×
